Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. CLNN.NASDAQ

Clene Inc. (CLNN NASDAQ) stock market data APIs

$4.42 -0.07(-1.6%) as of July 26, 2024
Price chart is built with Anychart

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

Clene Inc. Financial Data Overview

4.49
4.42
-
4.6716
4.4001
4.23-15.8
28 700 K
6 435 K
620 K
-0.09
0.458
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'CLNN',
Type: 'Common Stock',
Name: 'Clene Inc.',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG00X3GTK66',
ISIN: NULL,
CUSIP: NULL,
CIK: '1822791',
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: '2020-12-31',
InternationalDomestic: NULL,
Sector: 'Consumer Defensive',
Industry: 'Packaged Foods',
HomeCategory: NULL,
IsDelisted: false,
}

Clene Inc. Fundamental Data is available in our Financial Data APIs

  • Net Revenue 620 K
  • EBITDA -37 317 000
  • Earnings Per Share -8.2
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Clene Inc. Earnings via APIs

  • Latest Release 2024-05-08
  • EPS/Forecast -0.08

Get Clene Inc. End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Clene Inc. latest news via APIs

Clene VISIONARY-MS Trial Data May Support CNM-Au8(R) as MS Treatment

LOS ANGELES, CA - (NewMediaWire) - January 24, 2024 - (InvestorBrandNetwork via NewMediaWire) - This original article is powered by IBN, a financial news, content creation and publishing company. Sig...

Clene Announces Significant Positive Results from LTE VISIONARY-MS Trial

LOS ANGELES, CA - (NewMediaWire) - January 10, 2024 - (InvestorBrandNetwork via NewMediaWire) - This original article is powered by IBN, a financial news, content creation and publishing company. Cle...
Do you have any questions?
support@eodhistoricaldata.com